The Fibrosis-4 (FIB-4) Index is a validated, non-invasive scoring system used to estimate the risk of advanced liver fibrosis in patients with chronic liver disease. It relies on routinely available laboratory values and has been widely adopted in primary care, endocrinology, gastroenterology, and hepatology settings due to its simplicity, low cost, and strong negative predictive value. Rather than serving as a diagnostic test, FIB-4 functions as a risk-stratification tool, helping clinicians identify which patients can be safely managed in primary care and which may benefit from additional testing or specialist referral. Clinicians and patients can calculate the score using the MDCalc FIB-4 calculator.

What Does the FIB-4 Index Measure?

The FIB-4 Index incorporates four clinical variables:

• Age (years)
• AST (aspartate aminotransferase, IU/L)
• ALT (alanine aminotransferase, IU/L)
• Platelet count (10³/μL)

These variables collectively reflect hepatocellular injury, inflammatory activity, and portal hypertension–related changes, making FIB-4 particularly useful for identifying patients at risk of advanced fibrosis (≥F3).

Clinical Interpretation of FIB-4 Scores

Standard Cutoffs (Adults <65 years)

• < 1.3 Low risk for advanced fibrosis Negative predictive value: 85–95%
• 1.3–2.67 Indeterminate risk Requires additional non-invasive testing (e.g., elastography)
• > 2.67 High risk for advanced fibrosis Specialty referral recommended

Age-Adjusted Cutoffs (Adults >65 years)

• < 2.0 → Low risk
• 2.0–2.67 → Indeterminate
• > 2.67 → High risk

Age adjustment is critical, as FIB-4 incorporates age into its calculation and may otherwise overestimate fibrosis risk in older adults.

Guideline-Supported Clinical Use

Major professional societies—including the American Association for the Study of Liver Diseases (AASLD), American Gastroenterological Association (AGA), and American Diabetes Association (ADA)—recommend FIB-4 as a first-line fibrosis assessment in patients with:

• Metabolic dysfunction-associated steatotic liver disease (MASLD)
• Type 2 diabetes
• Obesity or metabolic syndrome
• Persistent elevation of AST/ALT
• Alcohol-related liver disease
• Known hepatic steatosis on imaging
• Risk factors for viral hepatitis

In MASLD populations, a FIB-4 score <1.3 reliably excludes advanced fibrosis, allowing many patients to remain safely in primary care without immediate imaging.

Sequential Testing Strategies: Why FIB-4 Comes First

FIB-4 is most effective when used as part of a two-tier testing strategy:

1. Step 1: FIB-4 screening
2. Step 2: Elastography (VCTE/FibroScan or MR elastography) for indeterminate or high-risk scores

Sequential testing has been shown to:

• Reduce indeterminate results by ~20%
• Provide posterior probabilities of cirrhosis ≥89%
• Reduce the need for liver biopsy from ~33% to ~19%
• Improve diagnostic accuracy in both primary care and specialty settings

This approach is now endorsed by the AGA, ADA, and AASLD for patients with MASLD and cardiometabolic risk factors.

Comparison With Other Non-Invasive Fibrosis Tools

• NAFLD Fibrosis Score (NFS): Performs similarly to FIB-4 but yields a higher proportion of indeterminate results (~45% vs ~30%).
• Transient Elastography (VCTE): Higher diagnostic accuracy than FIB-4 but less accessible and more costly; ideal as a confirmatory test.
• Magnetic Resonance Elastography (MRE): Highly accurate and less affected by BMI, but limited by cost and availability.
• Enhanced Liver Fibrosis (ELF) Test: Strong prognostic value; best used as a secondary test, particularly in indeterminate FIB-4 cases.

Despite lower positive predictive value (≈63%), FIB-4’s high negative predictive value (≈96%) makes it exceptionally useful for ruling out advanced fibrosis.

Important Limitations

• Reduced accuracy in patients <35 years
• Reduced specificity in patients >65 years
• Approximately 30% of patients fall into the indeterminate range
• Does not directly measure liver stiffness
• Cannot distinguish fibrosis from cirrhosis

For viral hepatitis, particularly hepatitis C, different cutoffs apply (<1.45 low risk; >3.25 high risk), reflecting the populations in which FIB-4 was originally developed.

Key Takeaway

The FIB-4 Index is a practical, evidence-based, and guideline-endorsed tool for early identification of liver fibrosis risk. When used thoughtfully—particularly as the first step in a sequential testing strategy—it enables timely intervention, appropriate referral, and more efficient use of advanced imaging and specialty care.

References

• American Diabetes Association Professional Practice Committee (2025) Standards of care in diabetes—2026: comprehensive medical evaluation and assessment of comorbidities. Diabetes Care, 48(Suppl 1), pp. S52–S76.
• Castera, L., Rinella, M.E. and Tsochatzis, E.A. (2025) Noninvasive assessment of liver fibrosis. The New England Journal of Medicine, 392(14), pp. 1352–1364.
• Kanwal, F., Shubrook, J.H., Adams, L.A. et al. (2021) Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology, 161(5), pp. 1657–1669.
• Mózes, F.E., Lee, J.A., Selvaraj, E.A. et al. (2022) Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 71(5), pp. 1006–1019.
• Rinella, M.E., Neuschwander-Tetri, B.A., Siddiqui, M.S. et al. (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), pp. 1797–1835.
• Sterling, R.K., Lissen, E., Clumeck, N. et al. (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 43(6), pp. 1317–1325.
• Tapper, E.B. and Parikh, N.D. (2023) Diagnosis and management of cirrhosis and its complications. JAMA, 329(18), pp. 1589–1602.
• Tincopa, M.A. and Loomba, R. (2023) Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The Lancet Gastroenterology & Hepatology, 8(5), pp. 401–414.
• Wattacheril, J.J., Abdelmalek, M.F., Lim, J.K. and Sanyal, A.J. (2023) AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of NAFLD. Gastroenterology, 165(4), pp. 1080–1095.